Additionally, combined treatment with BZA and the CDK4/6 inhibitor palbociclib resulted in additional inhibitory potency of cellular proliferation in breast cancer cells expressing both WT and Y537S ERα without impacting BZA’s action. Here, CDK4 is linked to breast carcinoma.